Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of HKD 19.82 [1][5][11] Core Insights - The company has successfully licensed its SIM0613 (LRRC15 ADC) to France's Ipsen for an upfront payment of USD 45 million and a total deal value of USD 1.06 billion, marking the third licensing deal in 2025 and indicating the company's innovative drug pipeline is entering a monetization phase [1][2] - The SIM0613 ADC platform shows significant potential, with advantages demonstrated in preclinical models and no direct competitors in clinical stages, positioning it as a potential first-in-class (FIC) product globally [2][3] - The company is accelerating its global pipeline expansion, with multiple products and technology platforms poised for overseas exploration, including promising candidates in autoimmune and oncology fields [3][4] Financial Projections - The adjusted net profit forecasts for 2025, 2026, and 2027 are projected at RMB 1.18 billion, RMB 1.40 billion, and RMB 1.52 billion respectively, reflecting a compound annual growth rate (CAGR) of 14% from 2025 to 2027 [5][11] - The expected earnings per share (EPS) for the same years are RMB 0.45, RMB 0.54, and RMB 0.59, with a price-to-earnings (PE) ratio projected to be 33.19x for 2026 [5][11][12]
先声药业（02096）：SIM0613出海，创新平台全球潜力兑现启动